AbbVie revises FY 2025 adj. EPS guidance down $0.13 on $248M IPR&D charge

AbbVie Inc.

2025-Q1 EPS reported $0.72 revenue$13,343,000,000

Q1 2025 includes $248M pre-tax acquired IPR&D and milestones expense.
Q1 2025 adjusted diluted EPS guidance: $2.34-$2.38 (prior $2.47-$2.51).
Full-year 2025 adjusted diluted EPS guidance: $11.99-$12.19 (from $12.12-$12.32).
Revised guidance excludes AbbVie-Gubra GUB014295 licensing deal closed after Q1.
Company does not forecast future IPR&D milestones due to uncertainty.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.